Creo Medical hails UK health watchdog's review of its breakthrough medical technology
Proactive Investors – Creo Medical Group PLC (LON:) said the National Institute for Health and Care Excellence (NICE) has selected the company’s Speedboat Inject to be scoped and routed for guidance in the area of endoscopic submucosal dissection (ESD) of lower gastrointestinal lesions.
The UK health watchdog picked the device for review because it “anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources”.
It initiates a “multi-step process” where clinical and economic value is interrogated. This then may result in a NICE recommendation such as medical technologies guidance, which helps accelerate the adoption of efficient and effective medical technologies into the NHS.
Craig Gulliford, CEO of Creo Medical, said: “We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK. We look forward to the outcome of the final stages of the review process as NICE concludes its work.”
